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Abstract
Coronary artery disease (CAD) is a major cause of morbidity and mortality
worldwide. Coronary artery bypass graft (CABG) surgery is the
revascularisation strategy of choice in patients with diabetes mellitus and
complex CAD. Owing to a number of factors, including the ageing population,
the increased complexity of CAD being treated, concomitant valve and aortic
surgery, and multiple comorbidities, higher-risk patients are being operated on,
the result of which is an increased risk of sustaining perioperative myocardial
injury (PMI) and poorer clinical outcomes. As such, new treatment strategies
are required to protect the heart against PMI and improve clinical outcomes
following cardiac surgery. In this regard, the heart can be endogenously
protected from PMI by subjecting the myocardium to one or more brief cycles of
ischaemia and reperfusion, a strategy called “ischaemic conditioning”.
However, this requires an intervention applied directly to the heart, which may
be challenging to apply in the clinical setting. In this regard, the strategy of
remote ischaemic conditioning (RIC) may be more attractive, as it allows the
endogenous cardioprotective strategy to be applied away from the heart to the
arm or leg by simply inflating and deflating a cuff on the upper arm or thigh to
induce one or more brief cycles of ischaemia and reperfusion (termed “limb
RIC”). Although a number of small clinical studies have demonstrated less PMI
with limb RIC following cardiac surgery, three recently published large
multicentre randomised clinical trials found no beneficial effects on short-term
or long-term clinical outcomes, questioning the role of limb RIC in the setting of
cardiac surgery. In this article, we review ischaemic conditioning as a
therapeutic strategy for endogenous cardioprotection in patients undergoing
cardiac surgery and discuss the potential reasons for the failure of limb RIC to
improve clinical outcomes in this setting. Crucially, limb RIC still has the
therapeutic potential to protect the heart in other clinical settings, such as acute
myocardial infarction, and it may also protect other organs against acute
ischaemia/reperfusion injury (such as the brain, kidney, and liver).
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Introduction
Coronary artery disease (CAD) remains a leading cause of mor-
bidity and mortality worldwide. For patients with complex 
multi-vessel CAD, coronary artery bypass graft (CABG) sur-
gery is the revascularisation strategy of choice, as it offers sur-
vival advantage when compared to multi-vessel percutaneous 
coronary intervention (PCI)1,2. Although advances in surgical and 
cardioprotection techniques have resulted in improved clinical 
outcomes following CABG surgery, changes in patient demo-
graphics have meant that higher-risk patients are now undergoing 
CABG surgery, all which have resulted in an increased risk of 
perioperative myocardial injury (PMI), which is detected by 
the release of serum cardiac biomarkers such as CK-MB, tro-
ponin I, and troponin T, and a higher operative mortality risk of 
5–6%3. These changes include (a) the ageing population (the pro-
portion of patients over 75 years old has increased by more than 
4.5-fold over the last decade with a 5-year mortality in this age 
group of 35%), (b) the presence of co-morbidities such as diabe-
tes and hypertension (the proportion of diabetic patients has risen 
from 15% to 22%, with an operative mortality of 2.6%), 
(c) more complex CAD is being operated on, and (d) concomitant 
valve and aortic surgery. Therefore, new treatment strategies are 
required to protect the heart from PMI during cardiac surgery in 
order to improve clinical outcomes in these higher-risk patients4,5. 
In this regard, the endogenous cardioprotective phenomenon 
of ischaemic conditioning has been investigated as a treatment 
strategy for protecting the heart and improving clinical outcomes in 
patients undergoing cardiac surgery.
Ischaemic conditioning: evolution of an endogenous 
cardioprotective strategy
The myocardium possesses an innate ability to protect itself 
from the detrimental effects of acute ischaemia/reperfusion 
injury (IRI). This can be harnessed by subjecting the heart to one 
or more non-lethal cycles of brief (5–10 minutes) ischaemia and 
reperfusion, a phenomenon that has been termed “ischaemic pre-
conditioning” (IPC)6–8. The concept of IPC was first discovered 
in a seminal study by Murry et al. in 19866, when they made the 
surprising observation that four 5-minute episodes of regional 
myocardial ischaemia and reperfusion could dramatically 
reduce myocardial infarct (MI) size following a lethal period of 
ischaemia. IPC has since been reported to exist in every spe-
cies and organ tested9. The IPC stimulus elicits two windows of 
cardioprotection: the first one (termed “classical IPC”) begins 
immediately following the IPC stimulus and lasts for 2–3 hours6, 
and the second one (termed the “second window of protection” 
or SWOP and first described in 199310,11) appears 12–24 hours 
after the IPC stimulus and lasts for 48–72 hours. The mechanisms 
underlying classical IPC have been extensively investigated, are 
complex, and involve the activation of plasma membrane recep-
tors (such as adenosine, opioids, acetylcholine, catecholamines, 
angiotensin II, bradykinin, and endothelin), the recruitment of a 
number of signal transduction pathways (such as nitric oxide-PKG, 
reperfusion injury salvage kinase12–14, and survivor activator fac-
tor enhancement15–18), the inhibition of mitochondrial permeability 
transition pore (MPTP) opening19–25, and the prevention of necrotic 
and apoptotic cell death. The delayed cardioprotective effect of 
the SWOP has been shown to be mediated by the transcription of 
several new proteins such as inducible nitric oxide synthase, heat 
shock proteins, and cyclo-oxygenase-226.
One major disadvantage of IPC is the need to apply the stimu-
lus prior to the index ischaemic insult, which is not possible in 
acute myocardial infarction (AMI). In this regard, Zhao et al. in 
200327 found that applying three 30-second cycles of ischaemia 
and reperfusion to the canine heart at the onset of reperfusion 
following a period of index ischaemia reduced MI size to a level 
on a par with IPC, a phenomenon that was termed “ischaemic 
postconditioning” (IPost) and that has provided a therapeutic 
strategy to protect the heart following AMI28. The signalling 
pathways underlying IPost are similar to classical IPC, although 
there are some differences7,9,29–31.
Crucially, both IPC and IPost require an invasive stimulus to 
be applied directly to the heart, thereby limiting their clinical 
application. In 1993, Pryzklenk et al.32 made the intriguing dis-
covery that applying the IPC stimulus (four 5-minute cycles of 
ischaemia and reperfusion) to the circumflex coronary artery 
could reduce MI size following a sustained occlusion of the left 
anterior descending coronary artery, demonstrating that the 
protection elicited by ischaemic conditioning could be trans-
ferred from one region of the heart to another, a phenomenon 
which has been termed “remote ischaemic conditioning” 
(RIC)32–35. Subsequent experimental studies demonstrated that 
the heart could be protected against AMI by applying the IPC 
stimulus to an organ or tissue remote from the heart, extending 
the concept of RIC to inter-organ ischaemic conditioning. The 
discovery that RIC could be induced by applying one or more 
cycles of brief ischaemia and reperfusion to the hind limb to 
reduce MI size36,37 facilitated the translation of RIC into the 
clinical setting with the use of a blood pressure cuff placed 
on the upper arm or thigh to induce one or more cycles of brief 
ischaemia and reperfusion to the limb (termed “limb RIC”)38. 
The mechanisms underlying limb RIC are not known, especially 
those conveying the cardioprotective signal from the limb to the 
heart. The current paradigm suggests that the limb RIC stimu-
lus generates a blood-borne transferrable factor, which then acti-
vates protective signal transduction pathways common to IPC and 
IPost, but the identity of the factor or factors remains unknown39. 
Several potential candidates have been proposed, including 
nitrite40, miRNA14441, and SDF42, but conclusive evidence for 
their role as the mediators of RIC is lacking. Interestingly, the neu-
ral pathway to the limb has to be intact for RIC to be effective43,44, 
suggesting that the underlying factor or factors may be a neuro-
transmitter or neuropeptide.
Ischaemic preconditioning and postconditioning in 
cardiac surgery
The first study to translate IPC into the clinical setting was by 
Yellon et al. in 199345; they demonstrated that subjecting the 
heart to two 3-minute cycles of global ischaemia and reperfusion 
by clamping and unclamping the aorta was able to preserve 
myocardial ATP levels45 and reduce PMI46 following cardiac sur-
gery. Since this pioneering study, a number of clinical studies 
have confirmed the cardioprotective effect of direct IPC in patients 
undergoing cardiac surgery, and a subsequent meta-analysis found 
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that IPC was able to reduce ventricular arrhythmias, lower ino-
trope use, and shorten intensive care unit stay when compared 
to control47. In 2007, Luo et al.48 were the first to apply IPost to 
the setting of cardiac surgery when they showed that applying 
IPost at the time of aortic unclamping, by re-clamping the aorta 
after 30 seconds and then unclamping it for 30 seconds, a cycle 
that was repeated twice, reduced PMI in children undergo-
ing cardiac surgery for Tetralogy of Fallot. A number of clinical 
studies have confirmed the efficacy of this IPost protocol in chil-
dren and adults undergoing cardiac surgery49,50. Given the invasive 
nature of the IPC and IPost protocols and the risk of thrombo- 
embolism from serial clamping and unclamping of the aorta, 
neither IPC nor IPost has been applied in the clinical setting.
Limb remote ischaemic conditioning in cardiac 
surgery
The first clinical trial to investigate limb RIC as a cardioprotec-
tive intervention in the setting of cardiac surgery was a small 
study of only eight patients by Günaydin et al. in 200051. They found 
that limb RIC, comprising two cycles of 3-minute arm ischaemia 
and 2-minute arm reperfusion, did not reduce PMI during car-
diac surgery. In 2002, Kharbanda et al.38 characterised the use of 
a blood pressure cuff to non-invasively deliver limb RIC (three 
5-minute cycles of ischaemia and reperfusion), demonstrating 
MI size reduction in a porcine model of acute myocardial IRI 
and improved endothelial function in human volunteers. The first 
clinical study to report a cardioprotective effect with limb RIC 
(three 5-minute cycles of arm ischaemia and reperfusion) was 
by Cheung et al.52, who found less PMI in children undergoing 
corrective cardiac surgery for congenital heart disease. Our group 
was the first to demonstrate less PMI (43% reduction in serum 
troponin T release over a 72-hour postoperative period) in adult 
patients undergoing CABG surgery with limb RIC (three 5-minute 
cycles of arm ischaemia and reperfusion) when compared to 
control53. Since these early studies, there have been a number of 
small positive studies confirming the cardioprotective effect of 
limb RIC in the setting of cardiac surgery, although there have 
also been several neutral studies (for comprehensive reviews, 
see 8,54–58). In a follow-up study of 329 CABG patients, 
Thielmann et al.59 found that limb RIC (three 5-minute cycles 
of arm ischaemia and reperfusion) reduced PMI and actually 
reduced all-cause mortality at 1.5 years by 73% when compared to 
control. However, this study was not prospectively designed 
or powered to test the effects of limb RIC on major clinical 
outcomes following cardiac surgery.
The effect of limb RIC on clinical outcomes following cardiac 
surgery has been recently investigated in three large prospective 
multicentre randomised controlled clinical trials, all of which 
failed to demonstrate any benefit with limb RIC on either PMI 
or major clinical outcomes. The first of these was a South 
Korean clinical study of 1,280 patients undergoing cardiac sur-
gery (CABG, valve, congenital heart disease, and aortic surgery), 
published in 2014 by Hong et al.60. They found in adult patients 
that limb RIC (four 5-minute cycles of ischaemia and reperfusion 
administered twice to the upper limb before and after cardiopul-
monary bypass) failed to improve the large primary composite 
endpoint (in-patient major adverse outcomes, including death, 
MI, arrhythmia, stroke, coma, renal failure or dysfunction, respi-
ratory failure, cardiogenic shock, gastrointestinal complications, 
and multi-organ failure). The German RIPHeart clinical trial did 
not find any improvement in the in-patient primary composite 
endpoint (death, non-fatal MI, stroke, and acute kidney injury) with 
limb RIC (four 5-minute cycles of arm ischaemia and reperfusion) 
in 1,385 adult patients undergoing cardiac surgery (CABG, valve, 
and aortic)61. Finally, the UK ERICCA clinical trial randomised 
1,612 higher-risk adult patients undergoing CABG with or 
without valve surgery (Additive Euroscore ≥5) to either limb 
RIC (four 5-minute cycles of arm ischaemia and reperfusion) or 
control and failed to find any improvement in the 1-year primary 
composite endpoint (cardiac death, non-fatal MI, stroke, and 
coronary revascularisation)62.
Why did limb remote ischaemic preconditioning 
fail to improve clinical outcomes following cardiac 
surgery?
The potential reasons why the three large clinical trials failed to 
find any reduction in PMI or improvement in short-term and 
long-term clinical outcomes following cardiac surgery with limb 
RIC include the following:
1. The clinical setting
CABG surgery may not be the optimum clinical setting to test 
the cardioprotective effects of limb RIC given that the extent of 
acute myocardial injury sustained in this clinical setting is rela-
tively small and the fact that cardioprotection has been optimised 
by improvements in surgical and anaesthetic techniques and the 
use of myocardial preservation strategies such as hypothermia and 
cardioplegia63. Moreover, patients undergoing concomitant valve 
surgery may be less amenable to RIC cardioprotection when 
compared to CABG surgery alone owing to the larger surgical 
trauma. Furthermore, RIC has been demonstrated in experimen-
tal studies to protect the heart mainly against acute IRI, whereas 
during cardiac surgery the causes of myocardial injury are 
multi-factorial and include inflammation (from cardiopul-
monary bypass), direct handling of the heart, and coronary 
micro-embolisation. As such, limb RIC may be more likely to 
be effective in the setting of AMI, in which the target for cardio-
protection is greater. In this regard, several clinical studies have 
reported a reduction in MI size with limb RIC applied prior to 
either thrombolysis64 or primary PCI65–71 in ST-elevation MI 
(STEMI) patients, and a large European multicentre randomised 
controlled clinical trial (the CONDI2/ERIC-PPCI trial) is under-
way investigating whether limb RIC can reduce cardiac death and 
hospitalisation for heart failure at 1 year72.
2. The limb remote ischaemic preconditioning protocol
Both the ERICCA and RIPHeart studies used a limb RIC proto-
col comprising four cycles of arm ischaemia and reperfusion61,62. 
Whether this is the optimal limb RIC protocol for cardioprotec-
tion in the setting of cardiac surgery is not known, as the RIC 
protocol has not been fully characterised in either the experimental 
animal or the clinical setting of acute myocardial IRI. Further work 
is therefore needed to investigate the most effective limb RIC (this 
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has recently been done in mice73), a task which would be made 
easier if a biomarker could be discovered, which can be used to 
assess the cardioprotective efficacy of limb RIC. However, this 
will be difficult given that the mechanisms underlying limb RIC 
remain unclear. It has also been suggested that the failure to fully 
blind the limb RIC protocol may have contributed to the positive 
results of the smaller clinical studies74. Achieving full blinding 
of the limb RIC protocol in the setting of cardiac surgery can be 
challenging but is possible using a cuff attached to a dummy arm 
beneath the surgical drape75,76.
3. Experimental animal models
The majority of experimental studies demonstrating cardiopro-
tection with limb RIC have used an experimental animal model 
of MI based on external occlusion of a coronary artery and 
have not tested limb RIC using a more relevant experimental 
animal model of cardiopulmonary bypass77. Furthermore, the 
experimental studies have for the most part included healthy, 
juvenile, small and large animals, making them far removed 
from the clinical setting of the typical middle-aged patient with 
IHD and multiple co-morbidities and co-medications (see 
below)77,78.
4. Co-morbidities
A number of co-morbidities (such as age, diabetes, hyperten-
sion, and hypercholesterolaemia) have been shown in experimen-
tal animal studies to attenuate the cardioprotection induced by 
IPC and IPost, and emerging data suggest that limb RIC is also 
susceptible to this phenomenon77–80. Although some experi-
mental studies have been able to recapitulate one individual co- 
morbidity (using diabetic, hypertensive, or hypercholesterolaemic 
animal models) when assessing cardioprotection, most patients 
have multiple co-morbidities and, furthermore, they are often 
on multiple treatments for their co-morbidities (anti-diabetic, 
anti-hypertensive, and lipid-lowering medication)—reproducing 
this in animal models will be extremely challenging58.
5. Co-medications
Patients undergoing CABG surgery receive a number of different 
medications, many of which have the potential to interfere with 
the cardioprotection elicited by limb RIC—these include anti-
diabetic medications, statins, angiotensin-converting enzyme 
inhibitors or angiotensin receptor blockers, calcium antago-
nists, beta-blockers, nitrates, morphine, inhaled anaesthetics, 
and propofol78. Of these, it has been suggested that the use of the 
intravenous anaesthetic propofol may have contributed to the fail-
ure of limb RIC to reduce PMI and improve clinical outcomes 
in the ERICCA and RIPHeart studies, given that over 90% of 
patients received propofol61,62; however, the data supporting this 
proposition are not conclusive. The first clinical study to draw 
attention to the potential confounding role of propofol on limb 
RIC was by Kottenberg et al.81, who showed that limb RIC was 
cardioprotective in the presence of isoflurane anaesthesia (n=19 
patients), but not propofol anaesthesia (n=14 patients) in the setting 
of CABG surgery. Interestingly, propofol anaesthesia in the 
absence of limb RIC had no cardioprotective effect, suggesting 
that propofol was somehow antagonising the cardioprotective 
effect of limb RIC in the setting of cardiac surgery. More recently, 
Bautin et al.82 showed in 48 patients (12 per group) undergoing 
aortic valve replacement surgery that the cardioprotective effect 
of limb RIC observed with sevoflurane anaesthesia was absent 
in the presence of propofol. In contrast, there have been several 
clinical studies reporting cardioprotection with limb RIC in cardiac 
surgery patients in the presence of propofol anaesthesia53,83,84. 
Furthermore, there are experimental data suggesting that pro-
pofol itself can reduce MI size85 and is cardioprotective in a 
porcine model of cardiopulmonary bypass86 through anti-oxidant 
and mito-protective mechanisms. Therefore, a suitably powered 
prospective randomised controlled clinical trial is required to test 
whether propofol anaesthesia antagonises the cardioprotective 
effect of limb RIC in the setting of cardiac surgery when compared 
to volatile anaesthesia.
Conclusions
Ischaemic conditioning has been investigated as an endog-
enous cardioprotective strategy for protecting the myocardium 
against PMI and improving clinical outcomes following cardiac 
surgery. Of these, IPC and IPost have been reported to reduce 
PMI, but, as they require direct application of the cardioprotective 
stimulus to the heart and because of the potential thrombo-
embolic risk from repetitive clamping of the aorta, their clinical 
application has been limited. In this regard, limb RIC, which 
allows the cardioprotective stimulus to be applied to the arm or 
leg by simply inflating a blood pressure cuff placed on the upper 
arm or thigh, has facilitated RIC’s use in the clinical setting 
of cardiac surgery, where it has been shown to reduce PMI. 
However, three large multicentre clinical studies have failed to 
find improved short-term and long-term clinical outcomes with 
limb RIC following cardiac surgery, questioning the role of limb 
RIC in the setting of cardiac surgery. Further studies are required 
to investigate why limb RIC failed to improve clinical outcomes 
in this clinical setting. However, limb RIC still has therapeutic 
potential to protect the heart in AMI patients and may also pro-
tect non-cardiac organs (such as the brain, liver, and kidney) from 
acute IRI.
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